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Abstract. Breast cancer is the most common cause of cancer 
mortality among women worldwide. Among the several factors 
associated with breast cancer development, angiogenesis plays 
an essential role and has currently emerged as a potential diag-
nostic, prognostic and therapeutic target. Protease-activated 
receptor 1 (PAR1) and fibroblast growth factor receptor 1 
(FGFR1) have important activities in tumor angiogenesis 
and progression. The aim of this study was to investigate the 
prognostic significance of these two receptors, hypothesising 
significant correlations between receptor expression in tumor 
angiogenesis and clinicopathological parameters customarily 
used in breast cancer prognosis and prediction. Formalin-fixed 
and paraffin-embedded samples of ductal invasive breast 
carcinomas were used to analyze the expression of PAR1 and 
FGFR1, in the tumor cells as well as in the tumor stroma, and 
further determine intratumoral microvessel density (iMVD) to 
quantify intratumoral angiogenesis. Correlations between PAR1 
and FGFR1 expression in tumor cells and stroma, iMVD and 
several clinicopathological parameters and molecular markers 
used in breast cancer diagnosis have been addressed. The corre-
lation between PAR1 and FGFR1 suggests an association of the 
two receptors with a more aggressive breast cancer phenotype 
and, consequently, a potential role during tumor progression. 
The results reported in the present study also emphasize the 
importance of microenvironmental factors in tumor progres-
sion, while precluding the positive association between iMVD 
and breast cancer aggressiveness.
Introduction
Breast cancer is a heterogeneous disease characterized by 
uncontrolled growth and spread of abnormal cells, being 
the most common cause of cancer mortality among women 
worldwide (1). Invasive breast cancer is the most common 
type of carcinoma in women, accounting for 22% of all female 
cancers and comprises a heterogeneous group of malignant 
epithelial tumors, characterized by the invasion of adjacent 
tissues and a marked tendency to metastasize to distant sites, 
differing with regard to their clinicopathological features and 
biological potential (2). The invasive ductal carcinoma of no 
specific type (IDC-NST) is the most common invasive breast 
cancer, accounting for 40-75% of all invasive tumors and is 
a histologically diverse group of lesions which includes all 
carcinomas that cannot be subclassified into one specialized 
type (3). Carcinogenesis is a multistep process mostly char-
acterized by the accumulation of genetic alterations that drive 
normal cells to malignant transformation (4). The majority 
of genes correlated with breast cancer development are also 
involved in pathways linked to the regulation of crucial biolog-
ical processes such as proliferation, apoptosis, angiogenesis, 
invasion and metastasis (5). Angiogenesis is involved in the 
development and progression of malignant tumors enabling 
cancer cells to acquire an adequate supply of oxygen, metabo-
lites and an effective way to remove waste products, and also 
provides a pathway for metastases. During tumor angiogen-
esis, the equilibrium between pro- and anti-angiogenic factors 
is lost and their relative contribution may change according to 
tumor type, tumor localization, as well as with tumor growth, 
regression and relapse. Pro- and anti-angiogenic molecules are 
released from tumor cells, endothelial cells (ECs), blood cells 
and the extracellular matrix. Among these factors, PAR1 and 
FGFR1 are key contributors to the angiogenic process (6-8).
Protease-activated receptors (PARs) are members of the 
G-protein coupled receptors (GPCR) superfamily that are 
expressed in several tissues by a variety of cells, being activated 
by proteolytic cleavage of their extracellular domains (9). 
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PAR1, one of the four members of the PAR family, is the 
predominant thrombin receptor in EC and is also detected in a 
variety of other cell types (10). PAR1 has been described as a 
crucial factor in angiogenesis, promoting numerous biological 
effects including coagulation, inflammation, mitogenesis and 
cell proliferation (11). The role of PAR1 in vascular biology 
and tissue remodelling is further stressed by the fact that 
factors activated upon thrombin-induced PAR1 signalling are 
known to be important during the process of vascular remodel-
ling. The expression and/or release of several growth factors, 
including FGF2, PDGF, VEGF (12,13), the upregulation of the 
insulin-growth factor receptor (IGFR)-1 (14), and the activa-
tion of fibroblast growth factor receptor 1 (FGFR1) (15) were 
shown to be induced in response to thrombin, metallopro-
teinase (MMP) 1 and more recently FGF1 (13). Accumulating 
evidence suggests that the receptor PAR1 modulates cell 
proliferation and motility in physiopathological cell inva-
sion processes, suggesting a role in initiating cancer growth 
and metastasis (16). Overexpression of this receptor has 
been detected in numerous human cancers, including breast 
cancer, where it has been described as being preferentially 
expressed in high-grade human breast carcinoma, correlating 
with the degree of invasiveness with differential metastatic 
potential (16). Moreover, there is evidence of the presence of 
PAR1 protein and mRNA not only in human malignant tumor 
cells, but also on the cell types forming the tumor microenvi-
ronment (17).
FGFR1 is a member of the FGFRs family (FGFR 1-4), 
a family of tyrosine kinase receptors, responsible for medi-
ating a number of actions induced by the members of the 
fibroblast growth factor family (FGF 1-24) group of pro-
angiogenic factors playing critical functions in each step of 
the angiogenic cycle. Aberrant regulation of FGF ligands and 
their receptors has been associated with prostate and breast 
tumorigenesis (18). Studies using inducible FGFR1 (iFGFR1) 
suggest that it is able to directly activate both proliferation and 
survival signals (antiapoptotic effects) within the mammary 
epithelium to rapidly induce hyperplastic lesions and regu-
late MMP secretion. Furthermore, the signalling complexity 
related to the iFGFR1-induced lesions, including the loss of 
myoepithelium and increased vascular branching suggest that 
other indirect effects mediated through stromal interactions 
also contribute to the tumor invasive phenotype (19). The aim 
of this study was to investigate the expression of PAR1 and 
FGFR1 in tumor cells and cells from the tumoral microen-
vironment in a series of invasive breast cancers and explore 
possible significant correlations with intratumoral microvessel 
density (iMVD), several breast cancer clinicopathological 
parameters and molecular markers.
Materials and methods
Tissue samples. A retrospective series of 224 formalin-fixed 
paraffin-embedded samples of ductal invasive breast carci-
nomas were used to construct tissue microarrays. The series 
of ductal invasive breast carcinomas had previously been 
characterized regarding clinicopathological parameters, such 
as histological grade, lymph node metastasis and patient 
survival (20). Samples from each case were collected from the 
donor sample with a 1 mm gauge cylinder and transferred to 
a receptor block using a manual tissue microarrayer (TMA) 
(Beecher Instruments, Sun Prairie, WI, USA). TMA sections 
(3 µm) were cut from the receptor block and processed as 
described in a previous study (20). Most of the immunohisto-
chemical characterization was previously reported and included 
the evaluation of several molecular markers, including estrogen 
receptor (ER), progesterone receptor (PR), epidermal growth 
factor receptor (EGFR) 2 (HER2), EGFR, P-cadherin (Pcad), 
keratin (CK) 5, CK14, P63, P53 and vimentin (20).
PAR1 and FGFR1 immunohistochemistry. Immunohisto-
chemical staining for PAR1 was carried out using Dako 
EnVision polymer (Dako Coorporation, Carpinteria, CA, USA) 
and the monoclonal antibody PAR1 (Thrombin R ATAP2: 
sc-13503 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA). Deparaffinized and re-hydrated TMAs were immersed 
in 1 mM EDTA buffer solution with 0.05% Tween 20, pH 7.4, 
and heated at 98˚C for 30 min in a bath. Following washing in 
phosphate-buffered saline (PBS), slides were incubated with 
3% hydrogen peroxide in methanol for 10 min, washed in PBS 
again and covered with a blocking serum for 10 min, prior to 
incubation with the primary antibody diluted at 1:100, over-
night at room temperature. Sections were sequentially washed 
in PBS, incubated with the polymer conjugated with secondary 
antibodies for 10 min and finally with 3,3'-diaminobenzidine 
(DAB Substrate System; Lab Vision Corporation, Fremont, 
CA, USA) for 10 min, between washes with PBS. TMAs 
were then counterstained with haematoxylin, dehydrated 
and mounted with the synthetic mounting medium Entellan 
(Merck, Darmstadt, Germany).
Immunohistochemical staining for FGFR1 was performed 
using the streptavidin-biotin peroxidase technique (LabVision 
Corporation) and the polyclonal antibody anti-FGFR1 (Flg 
C-15: sc-121 Santa Cruz Biotechnology, Inc.), raised against 
the C-terminus of the human form. TMAs were deparaf-
finized and rehydrated and heat-induced antigen retrieval was 
performed using a citrate buffer solution (10 mM) with 0.05% 
of Tween 20, pH 6.0, for 15 min in a microwave at 600 Watts. 
Following washing with PBS, the slides were incubated in 
a 3% hydrogen peroxide solution in methanol for 10 min to 
block endogenous peroxidase activity. The slides were then 
incubated with a blocking serum for 10 min and then for 2 h at 
room temperature with the primary antibody at 1:200 dilution. 
Slides were incubated with biotinylated goat anti-polyvalent 
antibody for 10 min, streptavidin peroxidase for another 
10 min and 3,3'-diaminobenzidine (DAB Substrate System; 
Lab Vision Corporation) for a further 10 min, between washes 
with PBS. TMAs were counterstained with haematoxylin, 
dehydrated and mounted with synthetic mounting medium 
Entellan (Merck).
Immunohistochemical staining in tumor cells and tumor 
stroma was independently assessed by two skilled patholo-
gists. Discrepancies were resolved by observation through a 
double-head microscope. Assessment of the immunohisto-
chemical results was based on a semiquantitative evaluation as 
specified in advance. The stroma of the tumors was classified 
as negative or positive, according to the presence or absence 
of positive expression for the two receptors in fibroblasts. The 
classification of positive immunoreactivity in tumor cells was 
carried out according to the percentage of immunopositive 
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cells: <10% was classified as negative; positive cytoplasmic 
immunostaining of PAR1 and FGFR1 ranged from 11 to 50% 
and from 51 to 100%, respectively.
Intratumoral microvessel density evaluation. iMVD was 
evaluated according to the cytoplasmic staining in blood endo-
thelial cells. Evaluation of positive reactions was performed by 
counting positive anti-factor VIII blood vessels, surrounding 
a visible lumen clearly separated from adjacent microvessels 
and from other connective tissue components. Packed vessels 
were considered as one vessel unit. Analysis was performed 
at a magnification of x200 (x20 objective lens and x10 ocular 
lens). An average of 10 hot spot fields was defined as iMVD. 
Counting of the vonWillebrand factor (anti-factor VIII) immu-
nohistochemical reactions was performed blindly.
Statistical analysis. For statistical analysis, contingency tables 
and Chi-square testing was performed using StatView 5.0 
(SAS Institute Inc., Cary, NC, USA) to estimate the relation-
ship between staining patterns of the different antibodies used. 
Survival curves were generated by the Kaplan-Meier method, 
using the SPSS 11.5 statistical software for patients with 
>2 years survival. Two values were considered significantly 
different when P<0.05.
Results
PAR1 expression. Among the 224 cases, 211 were eligible for 
statistical analysis. Expression of PAR1 in the tumor demon-
strated 2.4% negative cases, 8% positive <50% and 89.6% 
positive >50% (Fig. 1). PAR1 expression was also analysed in 
the stroma of the tumor, where 40.8% of the cases were consid-
ered negative and 59.2% positive. The immunohistochemical 
staining also revealed a strong expression of PAR1 in the endo-
thelial cells. PAR1 expression in tumor cells did not exhibit 
any significant correlation with any of the clinicopathological 
parameters, which included histological grade and lymph node 
metastasis, nor with patient survival, molecular subtype and/
or molecular markers, such as ER, PR, HER2, EGFR, Pcad, 
CK5, CK14, P63, P53 and vimentin (Table I). By contrast, 
statistically significant correlations were observed between the 
expression of PAR1 in the stroma and the molecular subtypes 
of breast cancer (P=0.0134), ER expression (P=0.0029), PR 
expression (P=0.0263) and adhesion molecule P-cadherin 
expression (P=0.0440; Table II). PAR1 expression in the 
stroma of the tumor was detected in a high percentage of cases 
among the basal and HER2 histological subtypes, as compared 
to the luminal subtype (Table III). Statistical analysis also 
revealed that a high percentage of ER cases (>70%) with a 
negative expression exhibited a positive expression of PAR1 
in the stroma, which was not observed with the ER-positive 
specimens. Similar results were observed between the expres-
sion of PAR1 in the stroma and the PR expression.
A significant statistical correlation was also observed 
between the expression of PAR1 in the stroma and the expres-
sion of Pcad, where approximately 70% of the Pcad-positive 
cases expressed PAR1. No significant statistical correlation 
was found between PAR1 expression in the tumor and patient 
survival (data not shown).
FGFR1 expression. The analysis of FGFR1 expression in 
the tumor cells revealed that 3% of the cases were negative, 
25.9% positive <50% and 71.1% positive >50% (Fig. 2). 
Expression of FGFR1 in tumor cells showed a significant 
correlation with tumor grade (P=0.0113) and with P53 
expression (P=0.0126; Table IV). The statistical analysis also 
showed an increasing percentage of tumor cases expressing 
FGFR1 (positive >50%), from grades I to III. Results also 
showed that FGFR1 is highly expressed (positive >50%) in 
the tumor cells in 88.6% of the P53-positive cases and in 66% 
of the negative ones. A significant correlation with CK14 
expression was observed (P=0.0253), although this correla-
tion may have resulted from the small number of positive 
cases expressing CK14. No significant correlation was found 
between the expression of FGFR1 in the tumor and patient 
survival (data not shown).
Figure 1. Positive PAR1 immunostaining was observed. PAR1 immuno-
reactivity was detected in the cytoplasm of the tumor cells (positive >50%), 
in the endothelial cells and stroma cells (magnification, x20).
Figure 2. Positive FGFR1 immunostaining was observed. FGFR1 immuno-
reactivity was detected in the cytoplasm of the tumor cells (positive >50%), 
and in the stroma (magnification, x20). 
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Regarding the stromal expression of FGFR1, results 
showed that only 9.6% of the cases were positive. Despite 
the low percentage of positive cases, significant correla-
tions were observed between the expression of FGFR1 in 
the stroma and histological grade (P=0.0238), breast cancer 
molecular subtypes (p=0.0063), ER expression (P=0.0127), 
Pcad expression (P=0.0041), P63 expression (0.0057) and P53 
expression (P=0.0058; Table V). An increasing percentage 
of FGFR1-positive cases were observed, from cases of 
histological grades I to III. Additionally, a higher percentage 
Table I. Correlation between PAR1 expression in the tumor cells and clinicopathological parameters.
   PAR1 tumor
 -------------------------------------------------------------------------------------------------------------------------------------------------------------------
Clinicopathological  Negative Positive <50% Positive >50%
parameters n (5 cases) % (n) (17 cases) % (n) (189 cases) % (n) P-value 
Histological grade
  I  98 4.1 (4) 10.2 (10) 85.7 (84) 0.3239 
  II  78 0 (0) 7.7 (6) 92.3 (72)
  III  29 3.4 (1) 3.4 (1) 93.1 (27)
Lymph node metastasis
  Positive  93 3.2 (3) 5.4 (5) 91.4 (85) 0.6419
  Negative 78 2.6 (2) 9 (7) 88.4 (69)
Molecular subtype
  Luminal 129 3.1 (4) 4.7 (6) 92.2 (119) 0.7403
  Basal  35 2.8 (1) 8.6 (3) 88.6 (31)
  HER2 20 0 (0) 10 (2) 90 (18)
ER
  Positive  126 3.2 (4) 4.8 (6) 92.0 (116) 0.0711 
  Negative 85 1.2 (1) 12.9 (11) 85.9 (73)
PR
  Positive  84 1.2 (1) 3.6 (3) 95.2 (80) 0.0905 
  Negative 127 3.2 (4) 11 (14) 85.8 (109)
HER2
  Positive  26 3.8 (1) 7.7 (2) 88.5 (23) 0.8812 
  Negative 180 2.2 (4) 7.8 (14) 90 (162)
EGFR 
  Positive  13 0 (0) 0 (0) 100 (13) 0.4465 
  Negative 198 2.5 (5) 8.6 (17) 88.9 (176)
Pcad
  Positive  52 0 (0) 9.6 (5) 90.4 (47) 0.3969 
  Negative 159 3.2 (5) 7.5 (12) 89.3 (142)
CK5
  Positive  51 2 (1) 5.9 (3) 92.1 (47) 0.7818 
  Negative 160 2.5 (4) 8.8 (14) 88.7 (142)
CK14
  Positive  4 0 (0) 25 (1) 75 (3) 0.3696 
  Negative 192 1 (2) 6.8 (13) 92.2 (177)
P63
  Positive  4 0 (0) 0 (0) 100 (4)  0.7888 
  Negative 207 2.4 (5) 8.2 (17) 89.4 (185)
P53
  Positive  48 2.1 (1) 10.4 (5) 87.5 (42)  0.7863 
  Negative 163 2.4 (4) 7.4 (12) 90.2 (147)
Vimentin
  Positive  33 3 (1) 6.1 (2) 90.9 (30) 0.7041
  Negative 155 1.3 (2) 8.4 (13) 90.3 (140)
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of FGFR1-positive cases in the basal and HER2 histological 
subtypes was observed when compared to the luminal subtype. 
It was also possible to observe a significant statistical corre-
lation between ER expression and FGFR1 expression in 
the stroma, where the ER-negative cases exhibited a higher 
percentage of positive FGFR1 expression when compared 
to the ER-positive cases. FGFR1-positive cases (68) were 
negative for ER expression and 61% of the FGFR1-negative 
cases were positive for ER expression, suggesting an inverse 
correlation between the expression of the two molecules. 
Table II. Correlation between PAR1 expression in the stroma and clinipathological parameters.
  PAR1 stroma
 ---------------------------------------------------------------------------------------------------------------------
Clinicopathological  Negative Positive  
parameters n (86 cases) % (n) (125 cases) % (n) P-value
Histological grade
  I 98 48 (47)  52 (51)  0.1007 
  II 78 37.2 (29)  62.8 (49)
  III 29 27.6 (8)  72.4 (21)
Lymph node metastasis
  Positive  93 39.8 (37) 60.2 (56) 0.8598
  Negative 78 38.5 (30) 61.5 (48)
Molecular subtype
  Luminal 129 49.6 (64) 50.4 (65) 0.0134
  Basal  35 22.9 (8) 77.1 (27)
  HER2 20 35 (7) 65 (13)
ER
  Positive  126 49.2 (62)  50.8 (64) 0.0029 
  Negative 85 28.2 (24)  71.8 (61)
PR
  Positive  84 50 (42)  50 (42) 0.0263 
  Negative 127 34.6 (44)  65.4 (83)
HER2
  Positive  26 42.3 (11) 57.7 (15) 0.8226 
  Negative 180 40 (72)  60 (108)
EGFR
  Positive  13 38.5 (5)  61.5 (8) 0.8619 
  Negative 198 40.9 (81)  59.1 (117)
Pcad
  Positive  52 28.8 (15)  71.2 (37) 0.0440 
  Negative 159 44.6 (71)  55.4 (88)
CK5
  Positive  51 47.1 (24)  52.9 (27) 0.2930 
  Negative 160 38.8 (62)  61.2 (98)
CK14
  Positive  4 50 (2)  50 (2) 0.6736 
  Negative 192 39.6 (76)  60.4 (116)
P63
  Positive  4 25 (1)  75 (3) 0.5173 
  Negative 207 41.1 (85)  58.9 (122)
P53
  Positive  48 31.2 (15)  68.8 (33) 0.1272 
  Negative 163 43.6 (71)  56.4 (92)
Vimentin
  Positive  33 33.3 (11) 66.7 (22) 0.4350
  Negative 155 40.6 (63) 59.4 (92)
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Another statistically significant correlation was found between 
FGFR1 and Pcad expression, revealing a higher percentage of 
Pcad-positive cases expressing FGFR1 as compared to their 
negative counterparts. The results also demonstrated a higher 
percentage of P53-positive cases expressing FGFR1 when 
compared to the P53-negative cases. A significant correlation 
between FGFR1 and P63 expression (P=0.0057) was also 
observed. Nonetheless, this correlation should be interpreted 
with caution due to the low number of positive cases expressing 
P63. No significant statistical correlations were found between 
the expression of FGFR1 in the stroma and patient survival 
(data not shown), nor between PAR1 and FGFR1.
Intratumoral microvessel density. iMVD evaluation was 
performed for 200 cases. The number of intratumoral blood 
vessels ranged between 0 and 47. The cases were grouped 
according to the cut off: One group had an iMVD of ≤8.5, the 
median iMVD, and a second group had an iMVD of >8.5. iMVD 
was correlated with the expression of PAR1 and FGFR1, in the 
tumor cells and stroma, as well as with several clinicopatho-
logical parameters and crucial breast cancer molecular markers 
(Table VI). A significant correlation was found between iMVD 
and the histological grade (P=0.022), with an inverse statisti-
cally significant correlation between breast cancer cases of 
grade III and iMVD. Regarding EGFR expression and iMVD, 
the results showed a higher percentage of iMVD ≤8 in positive 
EGFR cases when compared to iMVD >8.5 cases. A statisti-
cally significant correlation was also observed between iMVD 
and patient survival, showing that patients with an iMVD of 
>8.5 have better survival (data not shown). No significant 
correlations were observed between the iMVD with FGFR1 or 
PAR1 expression in the tumor cells or stroma.
Discussion
The analysis of PAR1 expression in a retrospective series of 
224 formalin-fixed paraffin-embedded samples of ductal inva-
sive breast carcinomas demonstrates, as suggested by previous 
studies, the expression of PAR1 in human malignant tumor 
cells as well as the cell types forming the tumor microenviron-
ment, and no expression of PAR1 in the surrounding stromal 
fibroblasts of the normal and benign breast epithelial cells (19). 
PAR1 expression in tumor cells did not exhibit a significant 
correlation with any of the clinicopathological parameters 
Table III. Correlation between PAR1 expression in the tumor cells and stroma related to the expression of FGFR1 positive 
reaction in the tumor cells and stroma.
A, PAR1 tumor cells.
  PAR1 tumor cells  
  ----------------------------------------------------------------------------------------------------------------------
  Positive <50% Positive >50% 
IpX reaction n (17 cases) % (n) (189 cases) % (n) P-value
FGFR1 tumor
  Negative 6 33.3 (2) 66.7 (4) 0.0511
  Positive <50% 48 12.5 (6) 87.5 (42) 
  Positive >50% 139 5 (7) 92.8 (129) 
FGFR1 stroma
  Positive  19 5.3 (1) 94.7 (18) 0.7647
  Negative 174 8 (14) 90.3 (157) 
B, PAR1 stroma.
  PAR1 stroma
   -----------------------------------------------------------------------------------------------------------------------
  Negative Positive 
IpX reaction n (86 cases) % (n) (125 cases) % (n) P-value
FGFR1 tumor
  Negative 6 50 (3) 50 (3) 0.6947
  Positive <50% 48 35.4 (17) 64.6 (31) 
  Positive >50% 139 41 (57) 59 (82) 
FGFR1 stroma 
  Positive  19 21.1 (4) 78.9 (15) 0.0773
  Negative 174 42 (73) 58 (101) 
  
IpX, immunohistochemical reaction.
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analysed, including histological grade, lymph node metastasis, 
patient survival, molecular subtype and the expression of 
several molecular markers, such as ER, PR, HER2, EGFR, 
Pcad, CK5, CK14, P63, P53 and vimentin.
The present study has shown the absence of statistically 
significant correlations of PAR1 expressed in the tumor cells. 
Specifically, the statistical analysis showed a significant asso-
ciation between the expression of PAR1 in the stroma and 
Table IV. Correlation between FGFR1 expression in the tumor cells and clinicopathological parameters.
   FGFR1 tumor
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------
Clinicopathological  Negative Positive <50%  Positive >50% 
parameters n (6 cases) % (n) (51 cases) % (n) (140 cases) % (n) P-value
Histological grade
  I 89 1.1 (1) 37.1 (33) 61.8 (55) 0.0113 
  II 74 5.4 (4) 16.2 (12) 78.4 (58) 
  III 28 3.6 (1) 14.3 (4) 82.1 (23) 
Lymph node 
metastasis
  Positive 84 1.2 (1) 26.2 (22) 72.6 (61) 0.3065
  Negative 75 5.3 (4) 22.7 (17) 72 (54)
Molecular subtype
  Luminal 118 1.7 (2) 27.1 (32) 71.2 (84) 0.2303 
  Basal 32 6.2 (2) 12.5 (4) 81.3 (26)
  HER2 20 0 (0) 20 (4) 80 (16)
ER
  Positive 115 1.8 (2) 27.8 (32) 70.4 (81) 0.3744 
  Negative 82 4.9 (4) 23.2 (19) 71.9 (59)
PR
  Positive 75 1.4 (1) 25.3 (19) 73.3 (55) 0.5305 
  Negative 122 4.1 (5) 26.2 (32) 69.7 (85)
HER2
  Positive 25 0 (0) 16 (4) 84 (21) 0.2574 
  Negative 167 3.6 (6) 27.5 (46) 68.9 (115)
EGFR
  Positive 13 0 (0) 15.4 (2) 84.6 (11) 0.5024 
  Negative 184 3.3 (6) 26.6 (49) 70.1 (129)
Pcad
  Positive 50 0 (0) 20 (10) 80 (40) 0.1580
  Negative 147 4.1 (6) 27.9 (41) 68 (100)
CK5
  Positive 50 4 (2) 22 (11) 74 (37) 0.7143
  Negative 147 2.7 (4) 27.2 (40) 70.1 (103)
CK14
  Positive 4 25 (1) 0 (0) 75 (3) 0.0253
  Negative 188 2.7 (5) 27.1 (51) 70.2 (132)
P63
  Positive 4 0 (0) 25 (1) 75 (3) 0.9350 
  Negative 193 3.1 (6) 25.9 (50) 80 (137)
P53
  Positive 44 2.3 (1) 9.1 (4) 88.6 (39) 0.0126
  Negative 153 3.3 (5) 30.7 (47) 66 (101)
Vimentin
  Positive 33 6.1 (2) 18.2 (6) 75.7 (25) 0.4315
  Negative 151 2.7 (4) 25.8 (39) 71.5 (108)
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more aggressive histological subtypes of breast cancer, more 
specifically with the basal and HER2 subtypes. Stromal cells, 
such as fibroblasts and inflammatory cells recruited to the 
tumor microenvironment highly expressed MMPs, and recent 
studies suggest that the MMP1 in the stromal-tumor microen-
vironment is capable of altering the behaviour of cancer cells 
through PAR1 to promote cell migration and invasion (11).
The fact that a high percentage of cases negative for ER 
and PR expression are positive for PAR1 expression in the 
stroma also suggests an association with poor prognosis (21). 
Table V. Correlation between FGFR1 expression in the stroma and clinicopathological parameters.
  FGFR1 stroma 
  ------------------------------------------------------------------------------------------------------------------------
Clinicopathological  Negative Positive 
parameters n (178 cases) % (n) (19 cases) % (n) P-value
Histological grade
  I  89 95.5 (85)  4.5 (4)  0.0238 
  II  74 87.8 (65)  12.2 (9)  
  III  28 78.6 (22)  21.4 (6)  
Lymph node 
metastasis
  Positive  84 88.1 (74) 11.9 (10) 0.2593
  Negative 75 93.3 (70) 6.7 (5) 
HER2
  Positive  25 88 (22)  12 (3)  0.7056 
  Negative 167 90.4 (151)  9.6 (6)  
Molecular subtype 
  Luminal   118 94.1 (111)  5.9 (7)  0.0063 
  Basal  32 75 (24)  25 (8)  
  HER2  20 85 (17)  15 (3)  
ER
  Positive  115 94.8 (109)  5.2 (6)  0.0127 
  Negative 82 84.1 (69)  15.9 (13)  
PR
  Positive  75 93.3 (70)  6.7 (5)  0.2669 
  Negative 122 88.5 (108)  11.5 (14)  
EGFR
  Positive  13 76.9 (10)  23.1 (3)  0.0896 
  Negative 184 91.3 (168)  8.7 (16)  
Pcad
  Positive  50 80 (40)  20 (10)  0.0041 
  Negative 147 93.9 (138)  6.1 (9)  
CK5
  Positive  50 90 (45)  10 (5)  0.9215 
  Negative 147 90.5 (133)  9.5 (14)  
CK14
  Positive  4 100 (4)  0 (0)  0.5156 
  Negative 188 90.4 (170)  9.6 (18)  
P63
  Positive  4 50 (2)  50 (2)  0.0057 
  Negative 193 91.2 (176)  8.8 (17)  
P53
  Positive  44 79.5 (35)  20.5 (9)  0.0058 
  Negative 153 93.5 (143)  6.5 (10)  
Vimentin
  Positive  33 84.8 (28) 15.2 (5) 0.2518
  Negative 151 91.4 (138) 8.6 (13) 
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Table VI. Correlation between intratumoral microvessel density and clinicopathological parameters.
  iMVD
  ---------------------------------------------------------------------------------------------
Clinicopathological  ≤ 8.5 >8.5 
parameters n % (100) % (100) P-value
Histological grade
  I   94 44.7 (42) 55.3 (52) 0.022
  II   73 46.6 (34) 53.4 (39)
  III   27 74.1 (20) 25.9 (7)
Lymph node metastasis
  Negative   77 44.2 (34) 55.8 (43) 0.609
  Positive   83 48.2 (40) 51.8 (43)
Molecular subtype
  Luminal A 117 55.6 (65) 44.4 (52) 0.417
  Luminal B     7 28.6 (2) 71.4 (5)
  HER2     4 50.0 (2) 50.0 (2)
  Basal   52 46.2 (24) 53.8 (28)
ER
  Negative   79 44.3 (35) 55.7 (44) 0.193
  Positive 121 53.7 (65) 46.3 (56)
PR
  Negative 123 45.5 (56) 54.5 (67) 0.110
  Positive   77 57.1 (44) 42.9 (33)
HER2
  Negative 172 50.0 (86) 50.0 (86) 0.981
  Positive   27 52.2 (14) 47.8 (13)
EGFR
  Negative 189 48.1 (91) 51.9 (98) 0.030
  Positive   11 81.8 (9) 18.2 (2)
CK5
  Negative 150 53.3 (80) 46.7 (70) 0.102
  Positive   50 40.0 (20) 60.0 (30)
CK14
  Negative 187 49.2 (92) 50.8 (95) 0.307
  Positive     4 75.0 (3) 25.0 (1)
P-Cad
  Negative 149 47.7 (71) 52.3 (78) 0.256
  Positive   51 56.9 (29) 43.1 (22)
P63
  Negative 196 50.0 (98) 50.0 (98) 1.000
  Positive     4 50.0 (2) 50.0 (2)
P53
  Negative 157 50.3 (79) 49.7 (78) 0.863
  Positive   43 48.8 (21) 51.2 (22)
FGFR1 tumor
  Negative     6 50.0 (3) 50.0 (3) 0.706
  Positive <50%   48 43.8 (21) 56.2 (27)
  Positive >50% 136 50.7 (69) 49.3 (67)
FGFR1 stroma
  Negative 172 50.0 (86) 50.0 (86) 0.370
  Positive   18 38.9 (7) 61.1 (11)
PAR1 tumor
  Negative     4 50.0 (2) 50.0 (2) 0.721
  Positive <50%   17 41.2 (7) 58.8 (10)
  Positive >50% 173 51.4 (89) 48.6 (84)
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Furthermore, the finding that a high percentage of cases posi-
tive for Pcad expression are also positive for PAR1 expression 
in the stroma suggests an association between PAR1 and 
invasive behaviour, since Pcad expression has been strongly 
associated with a high histological grade of ductal in situ breast 
carcinoma and poor survival, and has also shown a strong 
inverse correlation with ER expression in two types of breast 
carcinoma (in situ and invasive) (22,23). These results showed 
a strong association between the expression of PAR1 in the 
stroma and several clinicopathological parameters associated 
with more aggressive breast cancers, with worse response to 
treatment and consequently poor prognosis, highlighting the 
importance of the microenvironment in tumor expression, 
suggesting a potential role of PAR1 in autocrine and paracrine 
mechanisms of breast cancer progression (24).
Most of our results related to PAR1 expression are not in 
agreement with a previous study that demonstrated a signifi-
cant correlation between the expression of PAR1 in breast 
cancer and tumor grade in the presence of positive axillary 
lymph nodes in a series of 75 breast carcinoma specimens (16). 
Nonetheless, these differences may be explained by a different 
classification used for assessment of PAR1 expression in the 
two studies and the number of cases analyzed in each study.
PAR1 expression levels are directly correlated with degree 
of invasiveness in both primary breast tissue specimens and 
established cancer cell lines (25). This finding supports the 
results observed for PAR1 expression in the stroma and suggest 
active involvement of the former protein in a neoplastic 
development scenario. More studies are required to precisely 
explain the role of PAR1 in more aggressive tumor behaviour 
and poor patient prognosis.
As for FGFR1 expression, significant correlations were 
found between FGFR1 expression in tumor cells and tumor 
grade and P53 expression, showing an association between 
FGFR1 and parameters of cancer aggressiveness (2). These 
results are coherent due to the well-known correlation between 
P53 isoforms and solid malignant tumor progression (26). 
Furthermore, the significant correlations observed between 
FGFR1 expression in the stroma and the histological grade, 
molecular subtypes, ER, Pcad and P53 expression, emphasize 
the association of FGFR1 with more aggressive breast cancer 
phenotypes previously suggested by in vitro models (27,28).
It was previously demonstrated that when core 2 of the 
8p11.2-p12 is amplified, FGFR1 gene shows increased levels 
of mRNA and protein expression, as FGFR1 signalling is 
required for the survival of breast cancer cells harbouring 
FGFR1 amplification (29). Furthermore, FGFR1 amplification 
was observed in up to 10% of breast carcinomas and patient 
survival analysis revealed FGFR1 amplification to be an 
independent prognostic factor for survival, more specifically 
in patients with ER-positive tumors, where FGFR1 amplifica-
tion was the strongest independent predictor of poor outcome, 
suggesting that this gene is a useful therapeutic target for a 
subgroup of breast cancer patients with FGFR1 gene amplifi-
cation (30). We were careful to include the patient's outcome 
in the statistical analyses. To the best of our knowledge, this is 
the first study to consider the correlation of PAR1 and FGFR1 
expression in a large breast cancer cohort. Patient survival 
information was not available for all patients, limiting the 
evaluation of survival curves.
The tissue-specific expression of FGFs and FGFRs is 
critical factor in regulating FGFR signalling pathways and 
malignant transformation (31). FGF1 and FGFR1 were also 
demonstrated to be notably expressed in breast cancer cells. 
FGFR1 is also expressed in normal breast tissues but not FGF1, 
which suggests that breast cancer cells are able to release 
FGF1 and express FGFR1 in a neoplastic scenario, leading to 
a tumoral mass growing not only by a paracrine, but also by an 
autocrine mechanism (30). FGFR1 is able to directly activate 
both proliferation and survival signals (anti-apoptotic effects) 
within mammary epithelium to rapidly induce hyperplastic 
lesions and regulate MMP secretion (19). This finding suggests 
a crucial role for FGFR1 during tumor progression and prog-
nosis and may explain, in part, the results obtained for FGFR1 
in the tumor and stroma cells, reported in the present study.
Intratumoral angiogenesis, commonly assessed by deter-
mination of iMVD, has been suggested as a prognostic factor 
in solid tumors, as it has been shown on numerous occasions 
that higher iMVD is associated with poorer prognosis (32). 
Tissue microarrays are not the preferred option for determining 
iMVD; however, we opted for this method in order to maintain 
the same pattern of analyses for all cases. Our results did not 
show a statistically significant correlation between iMVD and 
clinicopathological parameters associated with cancer aggres-
siveness. The statistical significant inverse correlations we 
observed with histological grade III and for positive EGFR 
are debatable. Approximately 75% of grade III cases showed 
an iMVD of <8.5. Essentially, a minority of studies have not 
demonstrated an association between higher iMVD and poor 
prognosis. The apparent paradox between our findings and 
those of previous studies may be explained by several factors 
such as the lack of a standardized iMVD assessment (vessel 
counting and statistical analysis), use of different endothelial 
markers and immunostaining techniques with different speci-
ficity and sensitivity, the different size cohorts, different cut 
off and inadequate follow up (32). Regarding breast cancer, 
the controversies are even more pronounced since no signifi-
cant differences in tumor vascularity with different molecular 
subtypes have been found (33).
In conclusion, the results have shown that PAR1 and 
FGFR1 expression in breast carcinomas are correlated to 
several clinicopathological parameters of tumor behaviour, 
suggesting an association of PAR1 and FGFR1 with the more 
aggressive breast cancers, with possible worse response to 
treatment and consequently poor prognosis, emphasizing the 
importance of the microenvironment in tumor progression.
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